CONFIDENTIAL TREATMENT REQUESTED STOCK PURCHASE AGREEMENT among SPERO CANTAB, INC., SPERO CANTAB UK LIMITED, SPERO THERAPEUTICS, LLC, PBB DISTRIBUTIONS LIMITED, NEW PHARMA LICENSE HOLDINGS LIMITED, CANTAB ANTI-INFECTIVES LTD, and PRO BONO BIO PLC...Stock Purchase Agreement • September 22nd, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • England and Wales
Each of the Milestone Payments shall be payable a maximum of one (1) time only even if achieved more than one (1) time with one or more Products. For the avoidance of doubt, (x) each of the Milestone Payments shall become payable upon the occurrence of the associated Milestone Event, irrespective of the order in which the Milestone Events occur relative to each other, and (y) no amounts shall be due for subsequent or repeated achievements of any Milestone Event.
CONFIDENTIAL TREATMENT REQUESTED ASSIGNMENT AND LICENSE AGREEMENTAssignment and License Agreement • September 22nd, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This ASSIGNMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into as of May 9, 2016 (the “Effective Date”), by and between Vertex Pharmaceuticals Incorporated, with an address at 50 Northern Avenue, Boston, Massachusetts 02210 (“Vertex”) and Spero Trinem, Inc., with an address at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (“Spero”) and solely for the purposes of Section 13.15, Spero Therapeutics, LLC, with an address at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (“Parent”). Vertex and Spero each may be referred to herein individually as a “Party” or collectively as the “Parties.”
